Medicine details

ImageDoxorub-10
NameDoxorub-10
DosageInjection
Generic NameDoxorubicin Hydrochloride
Classes Antiinfective Agent
Anticancer/Antineoplastic Agent
Antibiotic
Diseases Breast Cancer
Cancer
Leukemia
Neuroblastoma
Ovarian Cancer
Stomach Cancer
CompanyTechno Drugs Ltd.

Drug Package Details

Strength10 mg/vial
Storage Condition
Origin CountryBangladesh
Commercial Pack1
Price per pack350.00
Cost per pack308.00
Package unit10 mg vial
Price per unit350.00
Cost per unit308.00
Discount0
Coupon
Remarks

Doxorubicin Hydrochloride

Doxorubicin is antineoplastic drug from the class anticancer antibiotics. Doxorubicin's cytotoxic effect on malignant cells and toxic effects on various organs are thought to be related to nucleotide base intercalation and cell membrane lipid binding activities. Intercalation prevents nucleotide replication as well as the activity of DNA and RNA polymerases. An important mechanism of doxorubicin HCl cytocidal activity appears to be the interaction of doxorubicin with topoisomerase II to form DNA-cleavable complexes.

Doxorubicin hydrochloride is indicated for the following neoplastic diseases-

  • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer 
  • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma 

Adjuvant Breast Cancer 

  • Doxorubicin HCl 60 mg/m2 is recommended as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles.

Metastatic Disease, Leukemia, or Lymphoma

  • When used alone, the recommended dose of doxorubicin HCl is 60 to 75 mg/m2 intravenously every 21 days. 
  • When combined with other chemotherapy drugs, the recommended dose of doxorubicin HCl is 40 to 75 mg/m2 intravenously every 21 to 28 days.
  • For heavily pretreated patients, elderly patients, or obese patients, consider using a lower doxorubicin dose within the recommended dose range or longer intervals between cycles. 
  • Cumulative doses greater than 550 mg/m2 are linked to an increased risk of cardiomyopathy.

Doxorubicin can cause the following side effects-

  • Cardiomyopathy and Arrhythmias
  • Secondary Malignancies
  • Extravasation and Tissue Necrosis 
  • Severe Myelosuppression 
  • Tumor Lysis Syndrome 
  • Radiation Sensitization and Radiation Recall
  • Alopecia
  • Nausea
  • Vomiting
  • Cardiomyopathy: Myocardial damage can occur with doxorubicin HCl, with incidences ranging from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when administered every 3 weeks. Concomitant cardiotoxic therapy raises the risk of cardiomyopathy even more. Assess the left ventricular ejection fraction (LVEF) before, during, and after doxorubicin HCl treatment.
  • Secondary Malignancies: Secondary Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) are more common in patients treated with anthracyclines, including doxorubicin.
  • Extravasation and Tissue Necrosis: Extravasation of doxorubicin HCl can result in severe local tissue injury and necrosis requiring wide excision and skin grafting.  Immediately terminate the drug, and apply ice to the affected area.
  • Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur. 

Contraindication

Contraindicated in patients with hypersensitivity to doxorubicin HCl.

Doxorubicin is contraindicated in-

  • Severe myocardial insufficiency 
  • Recent myocardial infarction 
  • Severe persistent drug-induced myelosuppression 
  • Severe hepatic impairment